Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nicotinamide phosphoribosyltransferase pseudogene 2 (NAMPTP2) is a nonfunctional genomic segment in humans, categorized as a pseudogene. Pseudogenes such as NAMPTP2 do not produce a functional protein but may share high sequence similarity with their related coding genes. They can be formed from duplication, mutation, or retrotransposition events. While some pseudogenes may acquire regulatory roles affecting gene networks, there is no evidence or data indicating a direct biological function, disease association, or therapeutic relevance for NAMPTP2. Pseudogenes are usually not considered valid drug or therapeutic targets as they do not encode functional proteins. Some pseudogenes may be implicated in regulatory gene networks or disease as RNA molecules, but no such evidence exists for NAMPTP2 specifically. Lack of information about biomarker utility, drug interactions, or safety concerns is due to its classification as a pseudogene and non-target status.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nicotinamide phosphoribosyltransferase pseudogene 2 (NAMPTP2).